Tumor targeted medicine as well as preparation method and application thereof

By developing the combination of Cx43 protein polypeptide and monoclonal antibody 3D8-ADC, the shortcomings in the treatment of metastatic testicular cancer in the prior art are solved, and effective targeted treatment of testicular cancer is achieved, especially in patients with ineffective cisplatin chemotherapy. A better treatment effect.

CN119074888AInactive Publication Date: 2024-12-06GUANGDONG JIEXU BIOMEDICAL TECH CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411231603.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-04
Publication Date
2024-12-06
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The prior art has shortcomings in the treatment of metastatic testicular cancer, especially in patients who are ineffective against cisplatin chemotherapy, and there is a lack of effective targeted treatment methods.

Method used

A drug targeting the treatment of testicular cancer, including the Cx43 protein polypeptide and the monoclonal antibody 3D8-ADC, was developed to form a drug combination for the target by screening polypeptide 2 and polypeptide 4, and the monoclonal antibody 3D8 targeting the GDF3 protein. Towards treatment.

Benefits of technology

This drug combination showed good therapeutic effects in targeted treatment of testicular cancer, which was more significant than that used alone, and provided a novel solution for metastatic testicular cancer.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119074888A_ABST
    Figure CN119074888A_ABST
Patent Text Reader

Abstract

The invention discloses a drug for targeted therapy of testicular cancer, the drug comprises a Cx43 protein polypeptide, the Cx43 protein polypeptide comprises a polypeptide 2 and a polypeptide 4, the amino acid sequence of the polypeptide 2 is PGCENVCYDK, and the amino acid sequence of the polypeptide 4 is VYTCKRDPCP. The medicine further comprises a monoclonal antibody 3D8-ADC, wherein the monoclonal antibody 3D8 is a monoclonal antibody which is specifically combined with the GDF3 protein. The medicine disclosed by the invention has a good targeted treatment effect on the testicular cancer, and a good reference is provided for targeted treatment research on the testicular cancer.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biotechnology, and specifically relates to a tumor targeting drug and a preparation method and application thereof. Background Art

[0002] Testicular cancer is the most common malignant tumor in young people, accounting for 1% to 1.5% of male malignant tumors. The peak age is 18 to 35 years old. The incidence in Western countries has increased in the past 20 years, and the combination of surgery and cisplatin-based chemotherapy has made the cure rate of testicular cancer patients greater than 90%. Despite this, 10% to 20% of testicular cancer patients with metastatic disease cannot be cured by cisplatin-based chemotherapy. Therefore, exploring new methods for targeted treatment of testicular cancer has great research value. Summary of the invention

[0003] In order to make up for the deficiencies of the prior art, the object of the present invention is to provide a testicular cancer targeted drug and a preparation method thereof.

[0004] Therefore, on one hand, the present invention discloses a drug for targeted treatment of testicular cancer, the drug comprising Cx43 protein polypeptide, the Cx43 protein polypeptide comprising polypeptide 2 and polypeptide 4, wherein the amino acid sequence of polypeptide 2 is PGCENVCYDK, and the amino acid sequence of polypeptide 4 is VYTCKRDPCP.

[0005] Preferably, the drug of the present invention further comprises monoclonal antibody 3D8-ADC, wherein monoclonal antibody 3D8 is a monoclonal antibody that specifically binds to GDF3 protein.

[0006] Preferably, the heavy chain variable region and light chain variable region sequences of the monoclonal antibody 3D8 of the present invention are shown as SEQ ID NO.1 and SEQ ID NO.2, respectively.

[0007] Preferably, the amino acid sequence of the monoclonal antibody 3D8 of the present invention that specifically binds to the GDF3 protein is LRHYEDMVVD.

[0008] Preferably, the drug of the present invention is a combination of polypeptide 2 and monoclonal antibody 3D8-ADC, or a combination of polypeptide 4 and monoclonal antibody 3D8-ADC.

[0009] In another aspect, the present invention also discloses a use of the polypeptide 2 and polypeptide 4 in the preparation of a drug for the targeted treatment of testicular cancer.

[0010] In another aspect, the present invention also discloses the use of the monoclonal antibody 3D8 in the preparation of a drug for targeted treatment of testicular cancer.

[0011] Based on the Cx43 protein, the present invention screened two best Cx43 protein polypeptides (polypeptide 2 and polypeptide 4), and these two polypeptides have good targeted therapeutic effects on testicular cancer.

[0012] In order to further enhance the targeted therapeutic effect of testicular cancer, the present invention further screened a monoclonal antibody targeting GDF3 protein (monoclonal antibody 3D8), and based on this monoclonal antibody, prepared an ADC drug for the treatment of testicular cancer. The ADC drug has a good targeted therapeutic effect on testicular cancer.

[0013] At the same time, the present invention combines polypeptide 2, polypeptide 4 and ADC drugs for targeted treatment of testicular cancer, achieving good targeted treatment effects, which are better than the effects of using them alone.

[0014] Therefore, the drug of the present invention has a good targeted therapeutic effect on testicular cancer, and provides a good reference for the targeted therapeutic research of testicular cancer. BRIEF DESCRIPTION OF THE DRAWINGS

[0015] Figure 1 Comparative results of the therapeutic effects of Cx43 protein peptide on nude mice.

[0016] Figure 2 Schematic diagram of the monoclonal antibody preparation process.

[0017] Figure 3 Comparison of the therapeutic effects of different combinations on nude mice.

[0018] Figure 4 Comparison of the therapeutic effects of different combinations on nude mice. DETAILED DESCRIPTION

[0019] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those generally understood by those skilled in the art of the present invention. The terms used herein in the specification of the present invention are only for the purpose of describing specific embodiments and are not intended to limit the present invention. The term "and / or" used herein includes any and all combinations of one or more related listed items.

[0020] Unless otherwise specified, the reagents, methods and equipment used in the present invention are conventional reagents, methods and equipment in the art. Unless otherwise specified, the reagents and materials used in the following examples are commercially available.

[0021] Example 1: Screening, preparation and testing of Cx43 protein polypeptides

[0022] Based on literature search, this researcher found that Cx43 (Connexin-43) protein is downregulated in testicular cancer and is associated with poor prognosis of patients [Yuan Min, Dong Shuying, Yao Yanxue, et al. Inhibitory effect of Connexin43 protein on autophagy of cisplatin-resistant testicular cancer I-10 / DDP cells [J]. Journal of Southern Medical University, 2019, 39(9)]. To this end, this researcher detected the Cx43 protein content in testicular cancer tissues and adjacent tissues collected from a hospital in Guangdong, and the results were consistent with those reported in the literature. Therefore, this researcher used this as a research target to conduct targeted therapy research on testicular cancer.

[0023] The amino acid sequence of Cx43 protein (GenBank: AAD37802.2) was analyzed and suitable peptides were designed, and some of the designed peptides are shown below:

[0024] Peptide 1: YDKSFPISHV; Peptide 2: PGCENVCYDK; Peptide 3: DEQSAFRCNT; Peptide 4: VYTCKRDPCP; Peptide 5: SLSAVYTCKR; Peptide 6: DCFLSRPTEK.

[0025] Forty 5-6 week old female BALB / c nude mice were randomly divided into 8 groups, 5 mice in each group, 7 of which were treated groups and one group was untreated as the control group. The specific groups are shown in Table 1. The Cx43 protein was from Kanglang Biotechnology (KL10373RP). The mouse testicular cancer cell line I-10 in the logarithmic growth phase was digested with trypsin and prepared into 5×10 7 / mL cell suspension, and subcutaneously inject 200μL of mouse testicular cancer cell line I-10 suspension into the right armpit of all nude mice. Continue to feed the nude mice for 2 weeks. After all nude mice have subcutaneous tumors, use a vernier caliper to measure the long and short diameters of the tumor, and calculate the tumor volume: tumor volume = π / 6×long diameter×short diameter×short diameter. Different peptides and Cx43 protein (all at a ratio of 1mg / kg) were injected into the nude mice through the tail vein, and all nude mice were killed after 2 weeks of treatment. The subcutaneous tumors of the killed nude mice were removed, weighed and recorded. The results showed ( Figure 1 ), the therapeutic effects of peptide 2 and peptide 4 were better, which were basically consistent with that of Cx43 protein.

[0026] Table 1 Different groups

[0027] Group drug Group drug Group 1 Peptide 1 Group 5 Peptide 5 Group 2 Peptide 2 Group 6 Peptide 6 Group 3 Peptide 3 Group 7 Cx43 protein Group 4 Peptide 4 Group 8 (control group) /

[0028] Example 2: Preparation of ADC drugs targeting GDF3 protein

[0029] 1. Preparation and testing of monoclonal antibodies against GDF3 protein

[0030] Literature reports show that GDF3 protein is highly expressed in testicular cancer and is significantly associated with its poor prognosis [Yan Zechen, Liu Tonghu, Yu Shuanbao, et al. Analysis of the expression and significance of GDF3 in testicular cancer based on TCGA and GTEx databases [J]. Chinese Journal of Andrology, 2023, 29(12): 980-985.]. Based on this, the researchers verified it and found that GDF3 protein is highly expressed in testicular cancer.

[0031] The recombinant human GDF3 protein (ab50061) was used to immunize mice to prepare monoclonal antibodies. The specific process is ( Figure 2 ) is as follows:

[0032] (1) Select 6-8 week old female BALB / c mice for the first immunization, GDF3 protein 50ug / mouse, with Freund's complete adjuvant, subcutaneous multiple injection, generally 0.5ml, at intervals of 2 weeks. The second immunization, the dosage route is the same as above, with Freund's incomplete adjuvant, at intervals of 2 weeks. The third immunization, the dosage is the same as above, without adjuvant, intraperitoneal injection, blood is collected 7 days later to measure its titer, and the immune effect is tested at intervals of 2 weeks. For booster immunization, the dosage is 50ug, intraperitoneal injection. After 3 days, the spleen is taken for fusion.

[0033] (2) Take the mice, remove their eyeballs and collect blood, and separate the serum as the positive control serum for antibody detection. At the same time, kill the mice by cervical dislocation, soak them in 75% alcohol for 5 minutes, fix them on a culture dish, and then lift up the skin on the left side of the abdomen to see the spleen. Use ophthalmic scissors and forceps, and use sterile surgical scissors to open the peritoneum in the clean bench. Take out the spleen and place it in a dish containing 10 ml of incomplete culture medium. Wash it gently, and carefully peel off the surrounding connective tissue. Place it on a stainless steel sieve in the dish, grind it into a cell suspension with a syringe needle, and then count it, so that the spleen cells enter the incomplete culture medium in the dish. Use a pipette to blow several times to make a single cell suspension. Usually 1×10 8 -2.5×10 8 splenocytes.

[0034] (3) 1×10 8 Splenocytes and 1×10 7Myeloma cells SP2 / 0 are mixed in a 50ml fusion tube, and incomplete culture medium is added to 30ml, and the mixture is thoroughly mixed. Centrifuge at 1000r / min for 5-10 minutes, and the supernatant is sucked as much as possible. Tap the bottom of the fusion tube on the palm of your hand to loosen and evenly distribute the precipitated cells; add 1ml of preheated 50% PEG with a 1ml pipette within 30s, and stir gently while adding. Let the pipette stand for 1min. Add preheated incomplete culture solution to terminate the PEG effect, and add 1ml, 2ml, 3ml, 4ml, 5ml, and 10ml every 2min, 800rpm for 5 minutes; discard the supernatant. Add 5ml of complete culture medium, gently blow and suck the precipitated cells to suspend and mix, and then add complete culture medium to 40-50ml. Dispense into 96-well cell culture plates, 100ul per well, and then culture the culture plates in a 37℃, 5% CO2 incubator. Add selection culture medium after 6h. 50ul per well, half of the medium was replaced with selection medium after 3 days. The growth of hybridoma cells was frequently observed, and when they grew to more than 1 / 10 of the bottom area of ​​the well, the supernatant was aspirated for antibody detection.

[0035] (4) Prepare mouse spleen cells as feeder cells. Prepare the hybridoma cell suspension to be cloned and dilute it to 3 different dilutions of 5, 10 and 20 cells per ml using HT medium containing 20% ​​serum. Add 5×10 4 -1×10 5 The ratio of cells was adjusted, and peritoneal macrophages were added to the above hybridoma cell suspension. Each hybridoma cell was dispensed into a 96-well plate, with 100ul per well. Cultured at 37°C and 5% CO2 for 6 days, antibodies were detected when clones were visible to the naked eye; observed under an inverted microscope, wells with only single clones growing were marked, and supernatants were taken for antibody detection. Cells from antibody-positive wells were expanded and cultured, and frozen. After this step, a total of 5 hybridoma cell lines were harvested, and the one with the highest effect was selected for subsequent experiments, named hybridoma cell 3D8.

[0036] (5) GDF3 protein was diluted to 10ug / ml with 50mM carbonate buffer at pH 9.6, and added to the wells of the ELISA plate at 100ul / well, and placed at 4℃ overnight. The liquid in the wells was discarded, and the wells were washed with PBST buffer 3 times, 3 minutes each time, and patted dry. 100ul of PBST buffer containing 1% BSA was added to each well for blocking at 37℃ for 2 hours; PBST buffer was washed 3 times; 100ul of hybridoma cell culture supernatant to be tested was added to each well, and positive, negative and blank controls were set up at the same time; incubated at 37℃ for 1 hour; washed, and patted dry. 5000-fold diluted HRP-labeled goat anti-mouse secondary antibody was added, 100ul per well, incubated at 37℃ for 0.5 hours, washed, and patted dry. TMB substrate solution was added, and 100ul of freshly prepared substrate solution was added to each well, and incubated at 37℃ for 10 minutes. The reaction was terminated with 2M H2SO4, and the OD450 value was read on an enzyme-linked immunosorbent reader. Result determination: P / N ≧ 2.1 is positive.

[0037] (6) Healthy female BALB / c mice aged 6 to 8 weeks were intraperitoneally injected with 0.5 ml of liquid paraffin. Seven days later, each mouse was intraperitoneally injected with 1×10 6 The hybridoma cell 3D8 was observed for 7 days, and the ascites was collected after the abdominal cavity of the mouse was obviously swollen. The supernatant was the ascites, which was packaged, labeled and used for later use. The ascites was centrifuged for 15 minutes (4000rpm, room temperature), and the supernatant was taken and purified using a Protein G column. The concentration of the purified antibody (monoclonal antibody 3D8) was determined using the BCA method, and the purified antibody was stored at -80°C for later use after packaging.

[0038] (7) The sequence of monoclonal antibody 3D8 and the recognition site for GDF3 protein were detected. The results showed that the heavy chain variable region and light chain variable region sequences of monoclonal antibody 3D8 were as shown in SEQ ID NO.1 and SEQ ID NO.2, respectively, and the amino acid sequence of monoclonal antibody 3D8 that specifically binds to GDF3 protein is LRHYEDMVVD.

[0039] 2. Preparation of ADC drugs

[0040] The monoclonal antibody 3D8 solution was mixed with the bleomycin aqueous solution, and 0.1M citrate buffer was added to adjust the pH to 4.0. The reaction was carried out at room temperature and the mixture was rotated for 48 hours. After the coupling was completed, an equal amount of 0.2M histidine buffer at pH 6.0 was added to quench the reaction, and then the quenched reaction solution was ultrafiltered with histidine solution to remove residual small molecules. Trehalose was added to the ultrafiltered solution to obtain the monoclonal antibody 3D8-ADC stock solution, and the stock solution was subjected to BCA protein content determination and stored at -80°C for later use.

[0041] Example 3: Targeted therapy for testicular cancer

[0042] Twenty-five 5-6-week-old female BALB / c nude mice were randomly divided into five groups, with five mice in each group. Four groups were used as treatment groups, and one group was used as a control group without treatment. The specific groups are shown in Table 2. The Cx43 protein was obtained from Kanglang Biotechnology (KL10373RP). The mouse testicular cancer cell line I-10 in the logarithmic growth phase was digested with trypsin and prepared into 5×10 7 100 μL / mL cell suspension was injected subcutaneously in the right armpit of all nude mice with 200 μL mouse testicular cancer cell line I-10 suspension. The nude mice were kept for 2 weeks. After all nude mice had subcutaneous tumors, the long and short diameters of the tumors were measured with a vernier caliper, and the tumor volume was calculated: tumor volume = π / 6 × long diameter × short diameter × short diameter. Different drugs were injected into the nude mice through the tail vein, and all nude mice were killed after 2 weeks of treatment. The subcutaneous tumors of the killed nude mice were removed, weighed and recorded.

[0043] The results show that Figure 3 ), the therapeutic effects of Group 2, Group 3 and Group 4 were better than those of Group 1, indicating that the combined treatment effect was better. However, Groups 2 and 3 used polypeptides, which are less likely to produce drug resistance than proteins. The inventors conducted a study on this, using Groups 2, 3 and 4 to treat nude mice for more than 3 times, and the results showed that the therapeutic effects of Groups 2 and 3 were better than those of Group 4 (such as Figure 4 shown).

[0044] Table 2 Different groups

[0045] Group drug dose Group 1 Monoclonal antibody 3D8-ADC 1mg / kg Group 2 Peptide 2 + monoclonal antibody 3D8-ADC 0.5mg / kg+0.5mg / kg Group 3 Peptide 4 + monoclonal antibody 3D8-ADC 0.5mg / kg+0.5mg / kg Group 4 Cx43 protein + monoclonal antibody 3D8-ADC 0.5mg / kg+0.5mg / kg Group 5 (control group) / /

[0046] The above embodiments are preferred implementation modes of the present invention, but the implementation modes of the present invention are not limited to the above embodiments. Any other changes, modifications, substitutions, combinations, and simplifications that do not deviate from the spirit and principles of the present invention should be equivalent replacement methods and are included in the protection scope of the present invention.

Claims

1. A drug for targeted treatment of testicular cancer, characterized in that: The drug comprises Cx43 protein polypeptides, wherein the Cx43 protein polypeptides comprise polypeptide 2 and polypeptide 4, wherein the amino acid sequence of polypeptide 2 is PGCENVCYDK, and the amino acid sequence of polypeptide 4 is VYTCKRDPCP.

2. The drug according to claim 1, characterized in that The drug also includes monoclonal antibody 3D8-ADC, wherein the monoclonal antibody 3D8 is a monoclonal antibody that specifically binds to the GDF3 protein.

3. The drug according to claim 2, characterized in that The heavy chain variable region and light chain variable region sequences of the monoclonal antibody 3D8 are shown in SEQ ID NO.1 and SEQ ID NO.2, respectively.

4. The drug according to claim 2, characterized in that The amino acid sequence of the monoclonal antibody 3D8 that specifically binds to the GDF3 protein is LRHYEDMVVD.

5. The drug according to any one of claims 1 or 2, characterized in that: The drug is a combination of polypeptide 2 and monoclonal antibody 3D8-ADC, or a combination of polypeptide 4 and monoclonal antibody 3D8-ADC.

6. Use of polypeptide 2 and polypeptide 4 as claimed in claim 1 in the preparation of a drug for targeted treatment of testicular cancer.

7. Use of the monoclonal antibody 3D8 as claimed in claim 2 in the preparation of a drug for the targeted treatment of testicular cancer.